Cornerstone Therapeutics to Acquire EKR Therapeutics, - Bloomberg

Cornerstone expands hospital product portfolio with cardiovascular products CARDENE(R) I.V. and RETAVASE(R) -- Transaction expected to be accretive in Q312 on a non-GAAP EPS basis -- Terms include initial $125 million in cash plus up to an ...

Cornerstone Therapeutics to Acquire EKR Therapeutics, Accelerating Expansion in Hospital Market - Yahoo Finance

CARY, NC and BEDMINSTER, NJ--(Marketwire -05/14/12)- Cornerstone Therapeutics Inc. (CRTX) Cornerstone expands hospital product portfolio with cardiovascular products CARDENE® I.V. and RETAVASE® Transaction expected to be accretive in Q312 on a ...

Cornerstone (CRTX) to Acquire EKR Therapeutics for $125M + Milestones - StreetInsider.com

The transaction is currently expected to close in late June 2012. As part of the transaction, Cornerstone will acquire product rights to CARDENE I.V. and RETAVASE. CARDENE I.V. is indicated for the short-term treatment of hypertension when oral therapy is ...

Side Effects of Lisinopril Pancreatitis - 1UP.COM

Calcium channel blockers - [Norvasc (Amplodipine) Cardizem LA, Dilacor XR, Tiazac (Diltiazem) Plendil (Felodipine) DynaCirc CR (Isradipine) Cardene, Cardene SR (Nicardipine) Procardia, Procardia XL, Adalat CC (Nifedipine) Sular (Nisoldipine) Calan ...

Side Effects of Lisinopril Weight Loss - 1UP.COM

Form of Calcium channel blockers are Diltiazem (Cardizem), nicardipine (Cardene), Nifedipine (Procardia) and verapamil (Calan or Isoptin) which is injurious in lower blood pressure. These side effects will continue in the subsequent post "Side effects of ...

House Call: Latest in stroke research - My Fox 8

The Stroke Center is also currently involved in a trial for hemorrhagic stroke treatment, researching the use of an FDA approved drug called Cardene to control the blood pressure of hemorrhagic stroke patients. The trial is measuring the ideal ...